[Calcium metabolism disorders in antiepileptic therapy].
D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001847:Bone Diseases / Q000139:chemically induced / Q000378:metabolism; D002118:Calcium / Q000037:antagonists & inhibitors / Q000378:metabolism; D002128:Calcium Metabolism Disorders / Q000139:chemically induced / Q000517:prevention & control; D002762:Cholecalciferol / Q000378:metabolism / Q000627:therapeutic use; D004790:Enzyme Induction / Q000187:drug effects; D004827:Epilepsy / Q000188:drug therapy; D006801:Humans; D007408:Intestinal Absorption; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D010634:Phenobarbital / Q000494:pharmacology; D010672:Phenytoin / Q000494:pharmacology; D051381:Rats; D013552:Swine
D000927:Anticonvulsants; D002762:Cholecalciferol; D010672:Phenytoin; D002118:Calcium; D010634:Phenobarbital
Calciumstoffwechselstörungen bei antiepileptischer Therapie.